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At Risk for Huntington's Disease
HD is a genetically caused brain disorder that causes uncontrollable bodily movements and robs
people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents
with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
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Huntington’s disease causes complex symptoms and attacks the brain –

the most difficult organ to access with drugs. Thus, current remedies only
help manage symptoms. They do not stop the disorder from progressing
and, ultimately, causing death.
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Now, building on groundbreaking research into the genetic roots of HD,
Triplet Therapeutics, Inc., is taking a bolder stance: restoring the idea of
transformative treatment onto the agenda by directly attacking the
disease's underlying causes.
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Founded in late 2018, Cambridge, MA-based Triplet aims to start a clinical

► 2018 (16)

trial in the second half of 2021 for a potential drug, for now called TTX3360, targeted at stopping the mutant huntingtin gene’s tendency for
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continued expansion with age. That expansion compromises brain cells
and triggers disease. Using the same mechanism, Triplet hopes to develop

► 2013 (30)

transformative treatments for many of the more than 50 other so-called
repeat expansion disorders (REDs). For REDs of the central nervous
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system, it would use the same drug as for Huntington’s.
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The DNA that comprises the mutations of many REDs – as with
Huntington’s – occurs in triplets of the letters of the genetic alphabet. This
helped inspire Triplet’s name. But other repeats, from 3-12 letters long,
have also been described. Also as in HD, the DNA in other repeat
expansion disorders grows longer and thus may cause disease.
“There's a lot of the genome that we actually don't know about, and a lot of
putative genes there that, frankly, we don't know functionally what they
do,” Triplet founder and CEO Nessan Bermingham, Ph.D., said in a
January interview on the podcast BioBoss. “So, I think of the opportunities
in our industry as we think about treating disease is very much going in
and trying to actually understand and segment these regions of the
genome to understand how targeting them may actually prevent or treat or
cure disease.”
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The efforts for treatments have taken “significant steps forward,” Dr.
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Bermingham observed.
Triplet secured $59 million in initial financing and investment. The
company’s scientific advisory board includes key researchers in the fight
against Huntington’s such as Harvard University geneticist James Gusella,
Ph.D., the leader of the team that discovered the huntingtin gene in 1993,
and Sarah Tabrizi, FRCP, Ph.D., a professor at University College London
and one of the chief medical collaborators in the development of the
historic Phase 1/2a HD gene-silencing clinical trial run by Ionis
Pharmaceuticals, Inc., followed by an in-progress Phase 3 trial run by

Triplet has also consulted with CHDI Foundation, Inc., the nonprofit
virtual biotech dedicated solely to developing HD therapies (drugs and/or
other treatments) and sponsor of the 15th Annual HD Therapeutics
Conference in February. Produced by former NBC-TV foreign
correspondent and global Huntington’s advocate Charles Sabine, this
year’s conference highlights video featured Triplet and its senior vice
president for research, Brian Bettencourt, Ph.D. Dr. Bettencourt was the
lead scientist in the design of TTX-3360.
As I wrote nine years ago, preventing onset in premanifest
(presymptomatic) gene HD gene expansion carriers like me has been the
“Holy Grail” not only for Huntington’s, but other neurological disorders,
given that brain damage starts many years before visible symptoms occur.
“To hear what has been up and coming in the past five years and to hear
what Triplet Therapeutics has been doing is so exciting for somebody like
me who is premanifest and who has kids, one who is at risk,” said leading
advocate Lauren Holder, 34, during her July 22 interview of Irina
Antonijevic, M.D., Ph.D., Triplet’s chief medical officer, on the Help4HD
Live podcast.

Above, Brian Bettencourt, Ph.D., Triplet’s senior vice president for
research, explains a slide illustrating the firm’s pathway to a potential
HD drug at the 15th Annual HD Therapeutics Conference (photo by Gene
Veritas, aka Kenneth P. Serbin). Below, Nessan Bermingham, Ph.D.,
Triplet founder and CEO (Triplet photo).
curehd.blogspot.com/2020/10/triplet-therapeutics-aims-to-transform.html
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Leveraging trailblazing insights of HD genetics
As a December 2019 news release stated, Triplet is “leveraging insights of
human genetics to target the underlying cause” of REDs.
Those insights from genetic data collected over decades in more than
9,000 people affected by HD have changed standard thinking about
Huntington’s genetics. This type of broad-ranging study is known as
GWAS, genome-wide association study.
“My company, Triplet Therapeutics, was quite literally founded based on
the information that came out of the Huntington’s GWAS,” Dr.
Bettencourt said in his interview with Sabine. “The GWAS provided us a
really, really rich list of good gene targets for drugs.” These genes modify
the age of onset and progression of HD.
“The research in HD has really driven the research in this entire field,” Dr.
Antonijevic told me in an interview via Zoom on October 4. From 20092010, she served as CHDI medical director. Later, she worked for Wave
Life Sciences, which is conducting an HD clinical trial with a drug similar
to the one developed by Roche for its historic clinical trial.
Dr. Antonijevic pointed to the “trailblazing” work of Harvard University
HD genetics researchers Dr. Gusella, Marcy MacDonald, Ph.D., and JongMin Lee, Ph.D. With others, they demonstrated why people with the same
repeat length in the huntingtin gene can experience widely different ages
of onset (click here to read more).
This might very well explain why HD struck my mother in her late 40s,
turned her into a debilitated, mere shadow of herself by her late 50s, and
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took her life at 68, while I, with the same degree of mutation, have reached
60 essentially healthy, without motor onset, and able to function normally.
Somatic expansion: a driver of disease
The disease-causing expansion of the relevant portion of the huntingtin
gene is the trinucleotide repeat CAG, letters in DNA alphabet. The
expansion over an individual’s lifetime is known as somatic expansion or
somatic instability. The breakthrough in HD genetics has revealed that socalled modifier genes linked to the speeding or slowing of somatic
expansion can hasten or delay the age of HD onset by just a few years or by
as many as 40.
Most of the modifiers contribute to the maintenance and repair of DNA,
which, in general, helps cells remain healthy. Scientists call this process
the DNA damage response (DDR) pathway.
“We tend to think of DNA as a fixed blueprint, an overarching plan for the
biological bricks and bridges that constitute our cells, organs, and bodies,”
a recent HDBuzz article explained of somatic instability. “But like any good
plan, DNA is actually dynamic and adaptable.”
Roche/Ionis achievement a ‘stimulus’ to other companies
Like Roche’s historic, in-progress Phase 3 gene-silencing clinical trial
(GENERATION HD1), the Triplet program will use an antisense
oligonucleotide (ASO), a synthetic modified single strand of DNA that can
alter production of certain proteins.
In its Phase 1/2a trial, the Roche ASO successfully reduced the amount of
mutant huntingtin protein in participants’ cerebrospinal fluid (CSF),
obtained from lumbar punctures (spinal taps). The CSF bathes the brain.
Roche researchers are looking hard for biomarkers (signs of disease and a
drug’s effectiveness) in the CSF. Triplet and other research programs are
also studying CSF.
Roche and its partner Ionis, which designed the drug candidate
Tominersen over nearly a decade, did the scientific heavy lifting required
to develop the first HD ASO and administer it safely to clinical trial
volunteers using lumbar punctures.
To date, Roche has not reported any serious adverse effects after the many
lumbar punctures done on the hundreds of volunteers in its clinical trial
program. The company expects to complete GENERATION HD1 and start
analyzing data in 2022.
“The demonstration in a clinical study that a drug can lower mutant
huntingtin levels was a critical development for the field,” Ignacio MuñozSanjuán, Ph.D., the CHDI vice president for translational biology, told
Sabine in the HD Therapeutics Conference highlights video. “It really
curehd.blogspot.com/2020/10/triplet-therapeutics-aims-to-transform.html
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provides stimulus to many other companies to use similar approaches and
similar methodologies to try to establish treatments that really benefit the
life of patients.”
Ionis has also been studying the control of somatic expansion as an
additional Huntington’s therapy. Researcher Jeff Carroll, Ph.D.,
presented on this topic at the HD Therapeutics Conference. In July he copublished a paper on this subject with a team of researchers, including two
Ionis scientists. The research demonstrates that lowering the huntingtin
protein with an ASO in mice and human neurons in a lab (but not yet in a
clinical trial) decreases somatic expansion and may also decrease the size
of the expansions.
"We remain committed to finding effective treatments for Huntington's
disease and are investigating multiple targets beyond lowering of
huntingtin in our drug discovery group and with academic
collaborators," Frank Bennett, Ph.D., Ionis executive vice president and
chief scientific officer, wrote me in an October 12 e-mail.
Taking the foot off the disease accelerator
Dr. Antonijevic indicated that Triplet has leveraged publicly available
knowledge gained from the Roche/Ionis program and others to plan
Triplet’s development program.
“I think it is great to see that there is trial activity,” she said. “Ultimately
the more trials with different approaches there are, the better the chance
that there will be a treatment for the patient.”

Dr. Irina Antonijevic (Triplet photo)
However, Dr. Antonijevic pointed out a key difference between Triplet’s
approach and Tominersen: lowering the amount of the mutant huntingtin
curehd.blogspot.com/2020/10/triplet-therapeutics-aims-to-transform.html
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protein does “nothing” to block the harmful expansion of the huntingtin
gene, because it does not “touch the DNA.”
As with all ASOs, the Triplet approach blocks the action of RNA. However,
Triplet’s drug will act “upstream” of the mutant, disease-causing gene itself
by targeting another gene that promotes huntingtin’s somatic expansion,
Dr. Antonijevic explained.
“This is why we say it’s upstream: it affects the huntingtin gene at the DNA
level,” she observed. “This is where we think it matters. The continuously
increasing toxicity of the mutant gene is stopped, because the expansion at
the DNA level is stopped.”
At the HD Therapeutics Conference, Dr. Bettencourt drew a
contrast between the huntingtin lowering done by the Ionis/Roche ASO
and Triplet’s targeting of somatic expansion. Huntingtin lowering is like
“putting a brake on the process,” he said. As a result, the drug is “not
dealing with the constant foot on the gas, whereby the DNA repeat is
continuing to expand.” Triplet is different: “our therapies quite simply seek
to remove that foot on the gas,” with the DNA no longer expanding, he
said.

Dr. Brian Bettencourt (Triplet photo)
Drug candidate now ready
Triplet announced the selection of its ASO drug candidate, TTX-3360, in
July. “TTX” stands for Triplet; 3360 is the number of the molecule.
Triplet very quickly developed its ASO because of “luck and expertise
combined,” Dr. Antonijevic told me, explaining that TTX-3360 has been
tested in animals, including non-human primates (monkeys). “We are
excited to move it forward.”
curehd.blogspot.com/2020/10/triplet-therapeutics-aims-to-transform.html
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To help select candidate compounds, Dr. Bettencourt stated at the
Therapeutics Conference that Triplet relied on computational screening,
experiments in animals, and tests in cells derived from HD patients. The
company has also used siRNAs, small interfering RNA molecules, to test
potential drug targets.
In its studies in non-human primates, one of Triplet’s test drugs was safe,
well-tolerated, and had significant “knockdown” (reduction, a desired
positive effect) on the targeted gene, Dr. Bettencourt added.
Dr. Antonijevic stated that TTX-3360 will target a modifier gene, but did
not reveal which one. The modifier gene itself is “not pathologic,” she
added. However, by reducing this gene’s expression as a protein that acts
on the huntingtin gene, Triplet hopes the deleterious expansion of the
huntingtin gene will slow or stop.
Triplet has not yet announced how it will deliver TTX-3360 in in the Phase
1/2 trial.
“Ultimately what we think is most important is that we get the drug to
those areas in the brain that are important to target when treating an
individual with Huntington’s disease, and we will let the science drive what
the right delivery is,” she said.
SHIELD HD: preparing for a clinical trial
Before Triplet can launch a study of its drug aiming to cure HD, it wants to
understand in greater detail how the disease progresses. It also wants to
confirm existing biomarkers and measure new ones to help track the
effectiveness of its drug.
Under Dr. Antonijevic’s leadership, last May Triplet initiated SHIELD HD,
a critical, two-year “natural history study” of approximately 60 HD gene
expansion carriers to help prepare the Phase 1/2 clinical trial of TTX-3360
that the firm hopes to launch in the second half of 2021. Triplet is
recruiting volunteers in Canada, France, Germany, the United Kingdom,
and the U.S.
“SHIELD HD” aligns with some of the letters in the study’s longer
scientific name, “but ultimately it reflects that we think of our approach as
a protection from the disease,” she told me.
A natural history study involves no “intervention or treatment,” she added.
“We are studying the disease as it would normally progress, using clinical
[observation] and biomarkers. So, it is really the natural course of the
disease.”
As part of the study, Triplet scientists are analyzing volunteers’ CSF, MRI
brain scans, blood, and data from cognitive tests, including HD-CAB, a
curehd.blogspot.com/2020/10/triplet-therapeutics-aims-to-transform.html
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refined “cognitive assessment battery” developed with input from the U.S.
Food and Drug Administration and researchers predominantly for
premanifest individuals, Dr. Antonijevic said in the Help4HD Live
interview.
“It is really a performance test,” Dr. Antonijevic told advocate Holder.
“This is something that does not require the physician or the investigator
to assess a patient, but it is the individual who performs the test.”
The cognitive tests provide a “snapshot in time” of the individual’s decline
because of HD and measures change over time, Dr. Antonijevic continued.
“It’s really more objective than, for instance, a rating scale.” (Physicians
use rating scales to determine a person’s level of HD.)
The study is also measuring DDR gene expression and the brain protein
neurofilament light chain, the latter a marker of disease progression.
SHIELD HD participants are also evaluated by a physician. Increasing
somatic expansion in HD models was associated with elevations of
neurofilament light chain, Dr. Bettencourt noted in his conference talk.

A slide from Dr. Bettencourt's presentation explaining SHIELD HD
(screenshot by Gene Veritas)
Participants before official onset
Because of Triplet’s ultimate goal to prevent onset of symptoms, SHIELD
HD is enrolling volunteers who have not yet experienced motor onset –
 the
involuntary movements and problems with gait that form the classic
criteria for diagnosing HD but have been called into question over the past
few decades.
As Dr. Antonijevic told advocate Holder, studies of postmortem HD brains
demonstrate that somatic expansion occurs many years before motor
onset.
“There are a number of symptoms that are measurable, trackable, and
predictable long before motor symptom onset,” Dr. Bettencourt noted at
curehd.blogspot.com/2020/10/triplet-therapeutics-aims-to-transform.html
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the Therapeutics Conference. He described the three groups of individuals
under study in SHIELD HD as “prodromal,” “peri-manifest,” and
“manifest.”
Prodromal refers to a period of years before motor onset, during which
gene carriers have already shown some cognitive and emotional
symptoms. Within the prodromal period, peri-manifest signifies the start
of so-called “soft” motor symptoms. Manifest individuals have an official
diagnosis of HD.
(For an in-depth discussion of premanifest and early-HD stages, click
here.)
Aiming to improve clinical trial design, researchers continue to refine
definitions of onset and disease progression. For instance, IBM has
produced a model of the disease with nine stages instead of the traditional
three. The traditional stages are after motor onset and do not include the
first two of early-stage categories indicated above.
SHIELD HD volunteers can do Phase 1/2 trial
Significantly, eligible SHIELD HD participants can later participate in the
TTX-3360 Phase 1/2 trial, Dr. Antonijevic explained to Holder. This will
enable the clinical trial investigators to compare an individual’s
performance in SHIELD HD, with no drug, to a period on treatment.
“This can be statistically a very powerful tool to measure the effect of a
therapy,” Dr. Antonijevic observed.
Triplet projects the trial as a Phase 1/2 so that it can test for the crucial
safety and tolerability typical of a Phase 1 but also perform measurements
that could “tell us a little bit more about the mechanism of our drug,” Dr.
Antonijevic told me. “We’ll be looking at the totality of data from this
Phase 1/2 study to inform the subsequent study.”
Helping hundreds of thousands of patients
Triplet’s leadership has emphasized how the company’s search for an HD
drug might work for other REDs, the repeat expansion disorders. These
include myotonic dystrophy type 1, fragile X syndrome, familial
amyotrophic lateral sclerosis (ALS), and spinocerebellar ataxias as well as
dentatorubral-pallidoluysian atrophy.
Large-scale genetic studies such as the Huntington’s GWAS “have
revolutionized the way we identify the underlying genetic drivers of repeat
expansion disorders,” CEO Bermingham stated in the news release about
SHIELD HD. “Our targeted approach is based on results from these
studies with our internal research providing insight into the central role
the DDR mechanism plays in these diseases. Our approach has the
curehd.blogspot.com/2020/10/triplet-therapeutics-aims-to-transform.html
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potential to address a broad range of repeat disorders addressing unmet
medical needs for hundreds of thousands of patients.”
As Bermingham stated in the BioBoss podcast, the potential now exists to
treat large numbers of diseases with the same drug.
According to Dr. Antonijevic, the number of REDs is actually increasing:
scientists are discovering new disease genes, and a growing number of
existing disease genes are now known to undergo somatic instability. She
believes that ranking them by number of affected people is not helpful, in
part because for each diseased person there can be many more
asymptomatic gene carriers.
For example, there are an estimated 41,000 HD-affected individuals in the
U.S., and more than 200,000 at risk for having inherited the gene. Some
140,000 people in the U.S. suffer from myotonic dystrophy type 1, and, Dr.
Antonijevic noted, additional people are at risk. Myotonic dystrophy type 1
symptoms include skeletal muscle weakness and myotonia (difficulty
relaxing muscles after use), cardiac dysfunction, respiratory dysfunction,
excessive daytime sleepiness, cataracts, and other abnormalities.
The focus on a one-drug-for-all approach distinguishes Triplet from other
companies that have developed ASOs against a specific disease gene, she
added.
Previously, scientists have sought a way to address energy loss in HDaffected brain cells and other disorders such as epilepsy as a possible path
to a common drug to correct the problems in bioenergetics (click here and
here to read more), but without success so far.
To further its strategy, on August 18 Triplet announced that it would take
part in a large international natural history study of myotonic dystrophy
type 1 aimed at deepening understanding of the disorder and developing
therapies.
Rescuing neurons – and people
Despite the COVID-19 pandemic, SHIELD HD – the natural history study
– is “definitely on schedule,” Antonijevic told me. Dr. Bettencourt said that
Triplet plans to provide a report on its research, including SHIELD HD, at
the 2021 HD Therapeutics Conference.
Triplet’s plan for a Phase 1/2 trial of TTX-3360 in 2021 is exciting news for
the HD community and beyond – not just for individuals with diseases
caused by repeat expansion disorders, but for the hundreds of thousands
of asymptomatic gene carriers (like me) fearful of their futures.
As Dr. Antonijevic said to Holder, “We think that, by intervening early, we
could rescue more neurons and have ultimately hopefully a greater
therapeutic benefit.”
curehd.blogspot.com/2020/10/triplet-therapeutics-aims-to-transform.html
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The Triplet drug development program became possible because of the
decades of research by scientists around the globe – and the participation
of thousands of HD families in research studies.
A growing number of companies are competing to develop HD therapies.
However, thanks to CHDI’s nonprofit role, academic researchers, and the
overall ethos of the HD cause, researchers have collaborated in remarkable
ways.
The HD community can take great comfort and pride in the hope that its
efforts can potentially benefit so many other rare and neurological disease
communities.
More than ever, #CureHD can become a dream fulfilled.
(Disclosure: I hold a symbolic amount of Ionis shares.)
Posted by Gene Veritas at 12:17 AM
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